−1.56EUR
−43.21 MEUR
4.35 MEUR
9.26 M
About NYXOAH SA
Sector
Industry
CEO
Olivier Taelman
Website
Headquarters
Mont-Saint-Guibert
Employees (FY)
146
Founded
2009
ISIN
BE0974358906
FIGI
BBG00X7DCB76
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of NYXH is 9.20 EUR — it has increased by 1.77% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange NYXOAH SA stocks are traded under the ticker NYXH.
NYXOAH SA is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
NYXH stock is 5.02% volatile and has beta coefficient of 1.45. Check out the list of the most volatile stocks — is NYXOAH SA there?
One year price forecast for NYXOAH SA has a max estimate of 25.40 EUR and a min estimate of 10.00 EUR.
NYXH earnings for the last quarter are −0.27 EUR per share, whereas the estimation was −0.43 EUR resulting in a 38.69% surprise. The estimated earnings for the next quarter are −0.36 EUR per share. See more details about NYXOAH SA earnings.
NYXOAH SA revenue for the last quarter amounts to 976.00 K EUR despite the estimated figure of 1.38 M EUR. In the next quarter revenue is expected to reach 1.74 M EUR.
Yes, you can track NYXOAH SA financials in yearly and quarterly reports right on TradingView.
NYXH stock has risen by 1.77% compared to the previous week, the month change is a 43.90% fall, over the last year NYXOAH SA has showed a 3.60% increase.
NYXH net income for the last quarter is −10.89 M EUR, while the quarter before that showed −7.61 M EUR of net income which accounts for −43.10% change. Track more NYXOAH SA financial stats to get the full picture.
Today NYXOAH SA has the market capitalization of 259.10 M, it has increased by 1.38% over the last week.
No, NYXH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NYXH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NYXOAH SA stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 146.00 employees. See our rating of the largest employees — is NYXOAH SA on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NYXOAH SA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NYXOAH SA stock shows the neutral signal. See more of NYXOAH SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NYXOAH SA future price: according to them, NYXH price has a max estimate of 25.41 EUR and a min estimate of 10.00 EUR. Read a more detailed NYXOAH SA forecast: see what analysts think of NYXOAH SA and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NYXOAH SA EBITDA is −43.29 M EUR, and current EBITDA margin is −995.54%. See more stats in NYXOAH SA financial statements.